Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(13 sites)
United States
Cedars-Sinai Medical Center, Los Angeles, California Johns Hopkins University, Baltimore, Maryland Massachusetts General Hospital, Boston, Massachusetts University of Michigan, Ann Arbor, Michigan Washington University School of Medicine, St Louis, Missouri Laura & Isaac Perlmutter Cancer Center at NYU Langone, New York, New York Univ of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania SCRI Oncology Partners, Nashville, Tennessee MD Anderson Cancer Center, Houston, Texas Huntsman Cancer Institute, Salt Lake City, Utah Virginia Cancer Specialists, Fairfax, Virginia Virginia Mason Medical Center, Seattle, Washington Australia
Peninsula and Southeast Oncology, Frankston, Victoria